The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial

Abstract Background Guselkumab, a fully human monoclonal antibody targeting the interleukin (IL)-23p19 subunit, is approved to treat adults with active psoriatic arthritis (PsA). In the Phase 3 DISCOVER-2 trial of 739 bilogico-naïve patients with active PsA, guselkumab 100 mg resulted in less radiog...

Full description

Bibliographic Details
Main Authors: Christopher T. Ritchlin, Laura C. Coates, Philip J. Mease, Désirée van der Heijde, Jiao Song, Yusang Jiang, May Shawi, Alexa P. Kollmeier, Proton Rahman
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Trials
Subjects:
Psoriatic arthritis
Spondyloarthritis
Randomized controlled trial
Radiographic data
Online Access:https://doi.org/10.1186/s13063-022-06945-y

Internet

https://doi.org/10.1186/s13063-022-06945-y

Similar Items